MindWalk Holdings Corp. reports developments in Bio-Native AI drug discovery, biologics research, and AI-driven therapeutic development. Company updates center on its patented HYFT technology and LensAI platform, which combine biological sequence, structure, function, literature analysis, and wet-lab validation for biologics discovery workflows.
Recurring news themes include financial results, enterprise platform contracts, North American biologics services activity, and product or program updates. Announcements have covered B Cell Llama for VHH nanobody discovery, B Cell Select, universal influenza research, functional-adjacency analysis for AI-designed therapeutics, and antibody or intrabody discovery work involving pathogenic TDP-43 in neurodegenerative disease.
MindWalk (NASDAQ: HYFT) announced a multi-year agreement with Teva Pharmaceuticals Australia to support a defined scope of antibody-discovery work. The deployment covers ReefIQ, its biological context layer, and specified LensAI analytical capabilities. Teva Australia will use generated predictions to support discovery decisions and antibody design optimization.
The agreement establishes a recurring-revenue platform relationship, continuing a collaboration dating to 2018. MindWalk will analyze approved data sources within the agreed scope. Deployment and use are subject to Teva Australia’s information-security, privacy, data-governance, scientific-review and human-oversight requirements.
MindWalk Holdings (NASDAQ: HYFT) announced that Thomas Lynch departed the company and ceased serving as Chief Business Officer, effective October 16, 2026.
The company said its commercial priorities remain unchanged, with work focused on delivering platform deployments already under contract and advancing pharmaceutical and partner engagements in progress. LensAI, its reasoning and application layer, remains in contracted, recurring arrangements with life sciences customers, running on ReefIQ. The commercial and business development team continues to report to Chief Executive Officer Jennifer Bath.
MindWalk (HYFT) published a white paper showing LensAI screened 890,634 antibody sequences for immune risk in under five hours. The run took 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by AMD EPYC processors. On an identical benchmark workload, Hpc8a delivered 37% faster performance and approximately 43% lower cost per sequence than an Intel-powered Amazon EC2 C8i configuration, without code changes.
An AMD-powered C8a configuration delivered 35% faster performance and approximately 29% lower cost per sequence against the same baseline. Results apply to the specific configurations evaluated, not all workloads. MindWalk intends the lower delivery cost to support additional volume without a proportional increase in compute expense as enterprise platform agreements move it toward contracted, recurring revenue. LensAI screening is commercially available.
MindWalk Holdings (NASDAQ: HYFT) announced three Boston-based leadership appointments as its pipeline advances toward preclinical studies testing whether candidates produce intended effects.
Zachary Maben joins as Director, Antigen Discovery & Protein Engineering from Arbor Biotechnologies. He will lead antigen discovery and protein engineering across the pipeline, linking computational discovery with laboratory validation. Joanne Lim joins from Orum Therapeutics as Director, Preclinical Development, with responsibilities including animal-study design, study oversight and candidate progression decisions. Shuji Sato, Vice President, Innovative Solutions, expands his responsibilities to include the pipeline.
The company says the appointments prepare it for preclinical efficacy studies and support decisions about which assets warrant continued investment. No preclinical efficacy results were announced.
MindWalk (NASDAQ: HYFT) outlined ReefIQ’s biological context platform and its licensing model for pharmaceutical discovery data and AI workflows.
ReefIQ has been commercially available since June 2026, while LensAI has contracted, recurring arrangements with life sciences clients. ReefIQ licensing is metered on data held in the platform and compute used against it, rather than seats. Relationships are multi-year by design, with deployments typically starting in data management and expanding into analytical tools and custom models.
MindWalk describes ReefIQ as a governed biological context layer—a shared representation of biological data—that different models can use. Its HYFT technology contains 660 million patterns and 25 billion relationships. The company expects ReefIQ and existing enterprise data platforms to be deployed together in pharmaceutical discovery workflows.
MindWalk (HYFT) appointed Kim Remizowski as an independent director on its Board of Directors, effective September 29, 2026. He will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board now comprises four directors, three of whom are independent.
Remizowski brings more than 35 years of institutional banking and fiduciary oversight experience. Most recently, he served as Director, Private Equity at Vistra, overseeing governance for investment funds and holding structures. His earlier roles included board service at Merrill Lynch Bank and Trust Company (Cayman), managing director responsibilities at DMS Bank & Trust, and 17 years at Royal Bank of Canada. The appointment comes as MindWalk expands contracted, recurring ReefIQ platform deployments with life sciences clients.
MindWalk (HYFT) reported a production deployment of the open-source OpenFold3 structure prediction model using AMD Inference Microservices on Vultr Kubernetes Engine, powered by AMD Instinct MI325X GPUs.
The company ran end-to-end production workloads across proteins, RNA, DNA, ligands and antibody-antigen complexes inside its ReefIQ-governed discovery workflows. A production-grade prediction environment was deployed in minutes, and antibody-antigen inference time was approximately 5x faster than in MindWalk’s prior environment. The deployment validates MindWalk’s model-agnostic architecture, expands compute capacity beneath ReefIQ as enterprise partners onboard, and independently validates AMD Inference Microservices for OpenFold3 in a life sciences production setting.
MindWalk (HYFT) reported fiscal Q1 2027 revenue of $3.8 million, up 21% year over year, with gross margin expanding to 58.6% from 48.3%.
Gross profit rose 47% to $2.2 million as cost of sales held near $1.6 million. Operating expenses increased 47% to $8.4 million, driving an operating loss of $6.1 million and net loss from continuing operations of $6.1 million, or $0.13 per share, compared with $4.1 million, or $0.09 per share, a year earlier. Adjusted EBITDA loss widened to $5.1 million from $3.7 million. Net cash used in operating activities improved slightly to $4.0 million, while cash declined to $7.6 million from $11.3 million at April 30, 2026.
The quarter included the commercial launch of ReefIQ™, and about 80% of the commercial funnel by value is now in partnership-structured engagements. After quarter-end, MindWalk secured a binding commitment for a senior unsecured revolving credit facility of up to US$30 million at a fixed 7.00% rate, with no financial maintenance covenants, no warrants or conversion feature, and no pledge of assets, to support its shift to recurring, platform-based revenue.
MindWalk Holdings (HYFT) secured a binding commitment for a senior unsecured revolving credit facility of up to US$30 million from Sanabil (Cayman) to fund biologics programs and commercial expansion.
The facility carries a fixed annual interest rate of 7.00% on drawn amounts only, an initial term of 36 months, and a possible 12‑month extension by agreement. It includes no financial maintenance covenants, no warrants, no equity conversion features, no asset pledge, and no material adverse change condition to closing. MindWalk is not obligated to borrow, may prepay without penalty, and will pay a one‑time 1.00% opening fee with no unused line fee. A definitive credit agreement consistent with the binding term sheet is targeted to close within 60 days.
MindWalk Holdings (HYFT) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026, at the Lotte New York Palace Hotel in New York.
A pre-recorded fireside chat featuring CEO Dr. Jennifer Bath and H.C. Wainwright biotechnology research managing director Dr. Swayampakula Ramakanth will be available on demand to registered attendees starting September 11, 2026, at 7:00 a.m. ET via the conference platform. Dr. Bath will also hold one-on-one investor meetings during the event.